Claims

1. A compound having Formula (2):



(2)

or pharmaceutically acceptable salts thereof;

wherein R^1 is halo or C_{1-6} alkyl;

R^2 is H;

R^3 is $(CR_2)_{0-2}SO_2R^{12}$, $(CR_2)_{0-2}SO_2NRR^{12}$, $(CR_2)_{0-2}C(O)O_{0-1}R^{12}$, $(CR_2)_{0-2}CONRR^{12}$, ~~CO_2NH_2~~ or cyano;

R^4 is an optionally substituted C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl; OR^{12}, $NR(R^{12})$, halo, nitro, SO_2R^{12}, $(CR_2)_pR^{13}$ or X; or R^4 is H;

R^6 is isopropoxy or methoxy;

one of R^8 and R^9 is $(CR_2)_qY$ and the other is C_{1-6} alkyl, cyano, $C(O)O_{0-1}R^{12}$, $CONR(R^{12})$ or $CONR(CR_2)_pNR(R^{12})$;

X is $(CR_2)_qY$, cyano, $C(O)O_{0-1}R^{12}$, $CONR(R^{12})$, $CONR(CR_2)_pNR(R^{12})$, $CONR(CR_2)_pOR^{12}$, $CONR(CR_2)_pSR^{12}$, $CONR(CR_2)_pS(O)_{1-2}R^{12}$ or $(CR_2)_{1-6}NR(CR_2)_pOR^{12}$;

Y is pyrrolidinyl, piperidinyl or azetidinyl, each of which is attached to the phenyl ring via a carbon atom;

R^{12} and R^{13} are independently an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R^{12} is H or C_{1-6} alkyl;

R is H or C_{1-6} alkyl;

n is 0-1;

p is 0-4; and

q is 0.

2. The compound of claim 1, wherein R^3 is SO_2R^{12}, SO_2NH_2, SO_2NRR^{12}, ~~CO_2NH_2,~~ $CONRR^{12}$, $C(O)O_{0-1}R^{12}$, or cyano; and R^{12} is C_{1-6} alkyl, an optionally substituted C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, pyrrolidinyl, piperazinyl, piperidinyl or morpholinyl.

3. The compound of claim 1, wherein one of R^8 and R^9 is $(CR_2)_qY$ and the other is C_{1-6} alkyl; and n is 0.

4. The compound of claim 1, wherein said compound is selected from the group consisting of



(S)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine;



(R)-5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-2-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine;



5-chloro-N2-(2-isopropoxy-5-methyl-4-



(1)

or pharmaceutically acceptable salts thereof; wherein



W is ;

A^1 and A^4 are independently C;

each A^2 and A^3 is C;

R^1 is halo or C_{1-6} alkyl;

R^2 is H;

R^3 is $(CR_2)_{0-2}SO_2R^{12}$, $(CR_2)_{0-2}SO_2NRR^{12}$, $(CR_2)_{0-2}CO_{1-2}R^{12}$, $(CR_2)_{0-2}CONRR^{12}$, ~~CO_2NH_2~~ or cyano;

R^4 is H, an optionally substituted C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl; OR^{12}, $NR(R^{12})$, halo, nitro, SO_2R^{12}, $(CR_2)_pR^{13}$ or X;

R^5, $R^{5'}$, R^7 and R^{10} are H;

R^6 is an optionally substituted C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl; OR^{12}, $NR(R^{12})$, halo, nitro, SO_2R^{12}, $(CR_2)_pR^{13}$ or X;

R^8 and R^9 are independently C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo or X; and provided one of R^8 and R^9 is X;

R is H or C_{1-6} alkyl;

X is $(CR_2)_qY$;

Y is an optionally substituted heterocyclic ring comprising N, O and/or S and attached to A^2 or A^3 or both via a carbon atom of said heterocyclic ring when q in $(CR_2)_qY$ is 0;

R^{12} and R^{13} are independently an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, or a 5-7 membered heterocyclic ring comprising N, O and/or S; aryl or heteroaryl; or R^{12} is H, C_{1-6} alkyl;

p is 0-4; and

n and q are 0.

8. The compound of claim 7, wherein R^3 is SO_2R^{12}, SO_2NH_2, SO_2NRR^{12}, ~~CO_2NH_2,~~ $CONRR^{12}$, $CO_{1-2}R^{12}$, or cyano; and

R^{12} is C_{1-6} alkyl, an optionally substituted C_{3-7} cycloalkyl, C_{3-7} cycloalkenyl, pyrrolidinyl, piperazinyl, piperidinyl or morpholinyl.

9. The compound of claim 7, wherein R^6 is halo or OR^{12}, wherein R^{12} is C_{1-6} alkyl.

10. The compound of claim 7, wherein said compound is selected from the group consisting of

1



(2-(5-chloro-2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino) pyrimidin-4-ylamino)phenyl)(pyrrolidin-1-yl)methanone;

2



2-(5-chloro-2-(2-isopropoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenylamino) pyrimidin-4-ylamino)-N-cyclopentylbenzamide;

7

